These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11910332)

  • 41. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
    Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
    Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
    Cmelak AJ; Li S; Goldwasser MA; Murphy B; Cannon M; Pinto H; Rosenthal DI; Gillison M; Forastiere AA
    J Clin Oncol; 2007 Sep; 25(25):3971-7. PubMed ID: 17761982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
    [No Abstract]   [Full Text] [Related]  

  • 45. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
    Chang SJ; Hodeib M; Chang J; Bristow RE
    Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.
    Salah-Eldin MA; Wahba HA; Halim AA
    Indian J Cancer; 2012; 49(1):169-75. PubMed ID: 22842184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible mechanisms behind taxane-anthracycline sequencing.
    Sahin I; Ararat E; Altundag K
    Lancet Oncol; 2010 Jun; 11(6):514-5. PubMed ID: 20522380
    [No Abstract]   [Full Text] [Related]  

  • 48. Diagnosis of ovarian cancer.
    Sundar S; Neal RD; Kehoe S
    BMJ; 2015 Sep; 351():h4443. PubMed ID: 26328593
    [No Abstract]   [Full Text] [Related]  

  • 49. [Decision-making of treatment and relative problems about recurrent and drug-resistant gynecologic neoplasms].
    Xie X; Cheng XD
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):801-3. PubMed ID: 21211274
    [No Abstract]   [Full Text] [Related]  

  • 50. The clinical value of tumour markers in the management of ovarian cancer.
    Rustin GJ
    Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
    [No Abstract]   [Full Text] [Related]  

  • 51. Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer.
    Le T; Hopkins L; Kee Fung MF
    Gynecol Oncol; 2005 Jul; 98(1):39-44. PubMed ID: 15907986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ovarian cancer: the role of functional imaging as an end point in clinical trials.
    Sala E; DeSouza N; Lee SI; Atri M; Hricak H;
    Int J Gynecol Cancer; 2010 Aug; 20(6):971-8. PubMed ID: 20683404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comprehensive look at the early detection of ovarian cancer.
    O'Rourke J; Mahon SM
    Clin J Oncol Nurs; 2003; 7(1):41-7. PubMed ID: 12629933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
    Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
    Moore KN; Moxley KM; Fader AN; Axtell AE; Rocconi RP; Abaid LN; Cass IA; Rose PG; Leath CA; Rutledge T; Blankenship D; Gold MA
    Gynecol Oncol; 2007 Dec; 107(3):398-403. PubMed ID: 17997146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.
    Jørgensen TL; Teiblum S; Paludan M; Poulsen LØ; Jørgensen AY; Bruun KH; Hallas J; Herrstedt J
    Gynecol Oncol; 2012 Nov; 127(2):367-74. PubMed ID: 22800653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How CA 125 is used in the routine follow-up of ovarian cancer: a survey of 29 Italian hospitals.
    Gion M; Barioli P; Ponti A; Torri V; Mione R; Dittadi R
    Tumour Biol; 1998; 19(4):269-74. PubMed ID: 9679737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re: A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
    J Natl Cancer Inst; 2012 Oct; 104(19):1514; author reply 1514-5. PubMed ID: 22923512
    [No Abstract]   [Full Text] [Related]  

  • 60. Specific keynote: in the shadow of illness-supporting women with ovarian cancer.
    Maughan K
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S129-33; discussion S134-5. PubMed ID: 12586103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.